// App-Quantinova.ai

: Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Researchers

Presenter

  • Fadi Haddad

Principal Investigators

  • Nicholas Short

  • Nitin Jain

  • Emmanuel Almanza Huante

  • Koji Sasaki

  • Patrice Nasnas

  • Farhad Ravandi

  • Partow Kebriaei

  • Xuelin Huang

  • Marina Konopleva

  • Guillermo Garcia-Manero

  • Richard E Champlin

  • Tapan M. Kadia

  • Koichi Takahashi

  • Naval Daver

  • Joseph D. Khoury

  • Jeffrey L. Jorgensen

  • Sa A Wang

  • Jovitta Jacob

  • Rebecca Garris

  • Hagop Kantarjian

Medical Centers

  • MD Anderson Cancer Center, Houston, TX

  • Biostatistics, The University of Texas MD Anderson Cancer Center, Houston

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Hematopathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Leukemia, MD Anderson Cancer Center, Houston, TX

  • University of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, TX

  • University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • B-lymphocyte antigen CD20

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • 6-mercaptopurine

  • Allmercap

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Blinatumomab

  • Methotrexate

  • Vincristine

  • Cytarabine liposomal

  • Inotuzumab ozogamicin

  • Prednisone

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved